WeTrials
Recruiting

Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

What is this study?

This study is testing how well a combination of targeted medicines, immunotherapy, and standard chemotherapy works as a first-line treatment for adults with a fast-growing blood cancer called B-cell acute lymphoblastic leukemia. Researchers want to see if adding these newer immune treatments to chemotherapy helps fight the cancer better than chemotherapy alone.

Who can participate?

This study is currently recruiting adults with newly diagnosed B-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma who have not yet been treated or are early in their treatment. Participants need to meet specific health and organ function requirements set by the study team.

What will happen?

Participants will receive a combination of treatments that may include chemotherapy drugs, targeted antibody therapies, and supportive medications like steroids to fight the cancer cells. They will also have regular lab tests to check how their body responds to the treatment.

Where and when?

This study is currently recruiting participants and takes place at 1 site in the United States.

Key Points
  • 1Testing a combination of chemotherapy and immunotherapy for new leukemia patients
  • 2Currently recruiting new participants at one location in the United States
  • 3Involves detailed health screenings and regular lab monitoring

Related video

VJHemOnc: Dr. Nicholas Short on this trial's design and early results (December 2020)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.